Table 3 Neutralizing antibody (nAB) levels of Systemic Lupus Erythematosus (SLE) patients after SARS-CoV-2 vaccination compared to Healthy subjects. Table cells show the Fold-Changes (FC), 95% Confidence Intervals (95% CI) and p-values derived from comparing antibody titers between each treatment line group and the Healthy subjects, which are taken as reference. Comparisons are performed for subjects receiving and not currently receiving Glucocorticoids’ therapy (Corticoids and No-Corticoids columns), as well as for all patients overall (All columns). Estimations and p-values are derived from a linear model in which sex, age, time from vaccination, vaccine type and corticoids therapy were included as covariates for statistical control. FC: Fold-change; 95% CI: 95% confidence interval.
All | No-Glucocorticoids | Glucocorticoids | ||||
|---|---|---|---|---|---|---|
FC [95% CI] | p-value | FC [95% CI] | p-value | FC [95% CI] | p-value | |
Control (Reference) | 1 | – | 1 | – | 1 | – |
Not-treated | 0.61 [0.19, 1.94] | 0.3950 | 1.22 [0.42, 3.52] | 0.7059 | 0.30 [0.07, 1.25] | 0.0972 |
First-Line | 0.30 [0.11, 0.81] | 0.0179 | 0.61 [0.23, 1.62] | 0.3136 | 0.15 [0.05, 0.49] | 0.0022 |
Second-Line | 0.63 [0.23, 1.68] | 0.3463 | 1.26 [0.47, 3.40] | 0.6437 | 0.31 [0.10, 1.01] | 0.0519 |
Third-Line | 0.27 [0.10, 0.74] | 0.0119 | 0.54 [0.20, 1.48] | 0.2246 | 0.13 [0.04, 0.45] | 0.0015 |
